At first relapse in multiple myeloma, why does the speaker suggest prioritizing BCMA-directed therapies ahead of GPRC5D-targeted combinations?
GPRC5D-targeted agents cause on-target, off-tumor side effects that can be problematic for patients
GPRC5D-targeted combinations have shown no progression-free survival benefit over standard of care
GPRC5D-targeted agents are ineffective in patients with extramedullary disease